David J. Benjamin, Medical Oncologist at the Hoag Family Cancer Institute, sharted a recent article by him and colleagues on X:
“Why did sacituzumab govitecan fail in the TROPiCS-04 study for advanced urothelial carcinoma?
In European Urology Oncology, we discuss the potential roles of G-CSF, dosing approaches, and differences in patient population compared to the TROPHY-U-01 trial.”
Authors: David J. Benjamin, Arash Rezazadeh Kalebasty, and Nataliya Mar
More posts featuring David J. Benjamin.